Genomtec has developed the Genomtec ID mobile platform for genetic diagnostics, enabling rapid molecular testing at the point of care. The platform specifically addresses the need for timely detection of respiratory tract infections caused by viruses and bacteria, offering the only CE-IVD Marked solution of its kind in Europe.
Funding
$5.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
PAFounders
Product
Problem
Current methods for diagnosing respiratory tract infections often require laboratory equipment and can have long turnaround times, delaying appropriate treatment. This can lead to increased transmission rates, unnecessary antibiotic use, and prolonged illness.
Solution
Genomtec has developed the Genomtec ID platform, a mobile genetic diagnostic system designed for rapid molecular testing at the point of care. The platform enables fast and accurate detection of viral and bacterial pathogens responsible for respiratory tract infections. The Genomtec ID Respiratory Panel 5-Plex (RP5-PLEX) is a CE-IVD marked assay that simultaneously identifies multiple respiratory pathogens, providing clinicians with actionable results in a timely manner. This allows for informed treatment decisions, improved patient outcomes, and reduced healthcare costs.
Target Audience
The primary target audience includes healthcare providers, hospitals, and clinics seeking rapid and accurate diagnostic solutions for respiratory tract infections at the point of care.
Features
- Mobile platform enabling rapid genetic diagnostics at the point of care
- CE-IVD Marked Genomtec ID Respiratory Panel 5-Plex (RP5-PLEX) for detection of viruses and bacteria causing respiratory tract infections
- Multiplex assay capable of simultaneously detecting multiple pathogens
- Fast turnaround time for timely clinical decision-making